Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
PSDV's Cash to Debt is ranked higher than
82% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. PSDV: No Debt )
PSDV' s 10-Year Cash to Debt Range
Min: 0.47   Max: No Debt
Current: No Debt

Equity to Asset 0.61
PSDV's Equity to Asset is ranked higher than
66% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. PSDV: 0.61 )
PSDV' s 10-Year Equity to Asset Range
Min: 0.47   Max: 0.91
Current: 0.61

0.47
0.91
Interest Coverage No Debt
PSDV's Interest Coverage is ranked higher than
82% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.51 vs. PSDV: No Debt )
PSDV' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -12.17
M-Score: -3.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -561.41
PSDV's Operating margin (%) is ranked lower than
58% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. PSDV: -561.41 )
PSDV' s 10-Year Operating margin (%) Range
Min: -4862.16   Max: 39.44
Current: -561.41

-4862.16
39.44
Net-margin (%) -555.30
PSDV's Net-margin (%) is ranked lower than
58% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. PSDV: -555.30 )
PSDV' s 10-Year Net-margin (%) Range
Min: -4638.7   Max: 37.97
Current: -555.3

-4638.7
37.97
ROE (%) -154.55
PSDV's ROE (%) is ranked lower than
59% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. PSDV: -154.55 )
PSDV' s 10-Year ROE (%) Range
Min: -251.58   Max: 26.49
Current: -154.55

-251.58
26.49
ROA (%) -73.24
PSDV's ROA (%) is ranked lower than
58% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. PSDV: -73.24 )
PSDV' s 10-Year ROA (%) Range
Min: -135.65   Max: 20.35
Current: -73.24

-135.65
20.35
ROC (Joel Greenblatt) (%) -6721.23
PSDV's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. PSDV: -6721.23 )
PSDV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17971.88   Max: 21141.86
Current: -6721.23

-17971.88
21141.86
Revenue Growth (%) -58.10
PSDV's Revenue Growth (%) is ranked lower than
58% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. PSDV: -58.10 )
PSDV' s 10-Year Revenue Growth (%) Range
Min: -58.1   Max: 85
Current: -58.1

-58.1
85
» PSDV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PSDV Guru Trades in Q1 2013

Jim Simons 12,100 sh (-49.79%)
» More
Q2 2013

PSDV Guru Trades in Q2 2013

Jim Simons 45,000 sh (+271.9%)
» More
Q3 2013

PSDV Guru Trades in Q3 2013

Jim Simons 241,800 sh (+437.33%)
» More
Q4 2013

PSDV Guru Trades in Q4 2013

Jim Simons 57,000 sh (-76.43%)
» More
» Details

Insider Trades

Latest Guru Trades with PSDV



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.20
PSDV's P/B is ranked lower than
66% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. PSDV: 7.20 )
PSDV' s 10-Year P/B Range
Min: 0.43   Max: 11.73
Current: 7.2

0.43
11.73
P/S 39.10
PSDV's P/S is ranked lower than
87% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. PSDV: 39.10 )
PSDV' s 10-Year P/S Range
Min: 1.02   Max: 1040
Current: 39.1

1.02
1040
EV-to-EBIT 125.00
PSDV's EV-to-EBIT is ranked lower than
75% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. PSDV: 125.00 )
PSDV' s 10-Year EV-to-EBIT Range
Min: 5.4   Max: 37.5
Current: 125

5.4
37.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.30
PSDV's Price/Net Cash is ranked higher than
51% of the 219 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. PSDV: 12.30 )
PSDV' s 10-Year Price/Net Cash Range
Min: 2.02   Max: 246
Current: 12.3

2.02
246
Price/Net Current Asset Value 11.50
PSDV's Price/Net Current Asset Value is ranked lower than
54% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. PSDV: 11.50 )
PSDV' s 10-Year Price/Net Current Asset Value Range
Min: 1.88   Max: 136.67
Current: 11.5

1.88
136.67
Price/Tangible Book 9.90
PSDV's Price/Tangible Book is ranked lower than
73% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. PSDV: 9.90 )
PSDV' s 10-Year Price/Tangible Book Range
Min: 1.76   Max: 105.33
Current: 9.9

1.76
105.33
Price/Median PS Value 2.70
PSDV's Price/Median PS Value is ranked lower than
70% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. PSDV: 2.70 )
PSDV' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 50.2
Current: 2.7

0.1
50.2
Earnings Yield (Greenblatt) 0.80
PSDV's Earnings Yield (Greenblatt) is ranked lower than
65% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. PSDV: 0.80 )
PSDV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 18.4
Current: 0.8

0.8
18.4
Forward Rate of Return (Yacktman) -35.57
PSDV's Forward Rate of Return (Yacktman) is ranked lower than
53% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. PSDV: -35.57 )
PSDV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -38   Max: -15.7
Current: -35.57

-38
-15.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PV3A.Germany
PSivida Corp. was organized as a Delaware Corporation in March 2008. On June 19, 2008, it reincorporated from Western Australia to the United States. The company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products and two principal product candidates under development, which represent successive generations of its Durasert technology platform. It have developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). Its most recently approved product, ILUVIEN, is an injectable, sustained-release micro-insert delivering the corticosteroid fluocinolone acetonide (FAc) over a period of up to 3 years for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal, and marketing authorization is pending in Italy and Spain. The International Diabetes Federation has estimated that approximately 19.1 million people in these seven countries have diabetes, of which Alimera has estimated that approximately 1.1 million suffer from vision loss associated with DME. Alimera has announced its intention to proceed with the direct commercialization of ILUVIEN in Germany, the U.K. and France in 2013. It is pursuing the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (posterior uveitis) as another indication for the same injectable micro-insert used in ILUVIEN. It did not license this indication to Alimera. It are also developing a bioerodible, injectable micro-insert delivering latanoprost (the Latanoprost Product) to treat glaucoma and ocular hypertension. Its primary technology systems are Durasert and BioSilicon.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide